Known targets — ChEMBL curated mechanism
BRAFFLT1FLT3FLT4KDRKITPDGFRBRAF1RET
The experimentally established mechanism targets of Sorafenib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 5/20 | 1.00 |
| ▸ | RAF1 known ✓ | P04049 | 12/20 | 0.81 |
| ▸ | BRAF known ✓ | P15056 | 4/20 | 0.81 |
| ▸ | RET known ✓ | P07949 | 3/20 | 0.81 |
| ▸ | PDGFRB known ✓ | P09619 | 2/20 | 0.81 |
| ▸ | KIT known ✓ | P10721 | 2/20 | 0.81 |
| ▸ | FLT1 known ✓ | P17948 | 2/20 | 0.81 |
| ▸ | FLT4 known ✓ | P35916 | 2/20 | 0.81 |
| ▸ | FLT3 known ✓ | P36888 | 2/20 | 0.81 |
| ▸ | AURKB | Q96GD4 | 2/20 | 1.00 |
| ▸ | NTSR1 | P30989 | 1/20 | 1.00 |
| ▸ | MC4R | P32245 | 1/20 | 1.00 |
| ▸ | PAX8 | Q06710 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.81 |
| ▸ | ABCB11 | O95342 | 2/20 | 0.81 |
| ▸ | ABL1 | P00519 | 2/20 | 0.81 |
| ▸ | HTR1A | P08908 | 2/20 | 0.81 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.81 |
| ▸ | FGFR1 | P11362 | 2/20 | 0.81 |
| ▸ | PDGFRA | P16234 | 2/20 | 0.81 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sorafenib SCHEMBL15939735 | 1.00 | KDR (1.00) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL29919725 | 1.00 | KDR (1.00) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL18496409 | 1.00 | KDR (1.00) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL28204502 | 0.99 | KDR (0.98) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL3660939 | 0.99 | KDR (0.98) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL16051185 | 0.97 | KDR (0.94) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL3664023 | 0.97 | KDR (0.94) | KDRAURKBNTSR1MC4RPAX8 | |
| Cm-4307 SCHEMBL14673524 | 0.95 | KDR (0.90) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL19322 | 0.93 | KDR (0.87) | KDRAURKBNTSR1MC4RPAX8 | |
| Sorafenib SCHEMBL18264082 | 0.93 | KDR (0.86) | KDRAURKBNTSR1MC4RPAX8 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6932 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4743086-A2 | TREATING MYELOID DISORDERS | Mayo Foundation for Medical Education and Research (US) | 2026-05-20 | — | — | EP | claimed |
| EP-3841097-B1 | 2,6-BIS(((1H-BENZO[D]IMIDAZOL-2-YL)THIO)METHYL)PYRIDINE AND N2,N6-DIBENZYLPYRIDINE-2,6-DICARBOXAMIDE DERIVATIVES AND RELATED COMPOUNDS AS PHOSPHOINOSITIDE 3-KINASE (PI3K) INHIBITORS FOR TREATING CANCER | BIOMEDICAL RES FOUNDATION OF THE ACADEMY OF ATHENS BRFAA (GR) | 2026-05-20 | — | — | EP | claimed |
| WO-2026102161-A1 | METHODS OF TREATING OVARIAN AND PANCREATIC CANCER | CONCARLO THERAPEUTICS, INC. (US) | 2026-05-15 | — | — | WO | claimed |
| US-20260132141-A1 | PROTEIN PHOSPHATASE 2A ACTIVATORS | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INCORPORATED (US) | 2026-05-14 | — | — | US | claimed |
| WO-2026087695-A1 | TREATMENT FOR METABOLIC DISORDER | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| WO-2026087680-A1 | TREATMENT FOR CARDIOVASCULAR DISEASE | SAPREME TECHNOLOGIES B.V. (NL) | 2026-04-30 | — | — | WO | claimed |
| EP-4712963-A2 | SMALL MOLECULE INHIBITORS OF P27 | Concarlo Therapeutics, Inc. (US) | 2026-03-25 | — | — | EP | claimed |
| EP-4709378-A1 | COMPOUNDS FOR NOS-RELATED CANCERS AND METHODS OF USE | Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. (IL) | 2026-03-18 | — | — | EP | claimed |
| US-20260069700-A1 | BRUSH PRODRUGS AND USES THEREOF | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2026-03-12 | — | — | US | claimed |
| US-12478683-B2 | Brush prodrugs and uses thereof | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2025-11-25 | — | — | US | claimed |
| US-20080227828-A1 | Aryl Ureas With Angiogenisis Inhibiting Activity | BAYER HEALTHCARE LLC | 2008-09-18 | — | — | US | claimed |
| EP-1968589-A2 | COMBINATIONS COMPRISING SORAFENIB AND INTERFERON FOR THE TREATMENT OF CANCER | Bayer Pharmaceuticals Corporation (US) | 2008-09-17 | — | — | EP | claimed |
| WO-2008070616-A2 | METHODS AND COMPOSITIONS RELATED TO HIF-1α | UNIVERSITY OF UTAH RESEARCH FOUNDATION (US) | 2008-06-12 | — | — | WO | claimed |
| US-20080124333-A1 | METHODS AND COMPOSITIONS FOR TREATING MELANOMA | UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY (US) | 2008-05-29 | — | — | US | claimed |
| WO-2008059052-A1 | IMPROVED METHODS OF USING PHOSPHOANTIGEN FOR THE TREATMENT OF CANCER | INNATE PHARMA (FR) | 2008-05-22 | — | — | WO | claimed |
| US-20080066741-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| WO-2007053574-A2 | COMBINATIONS COMPRISING SORAFENIB AND INTERFERON FOR THE TREATMENT OF CANCER | BAYER PHARMACEUTICALS CORPORATION (US) | 2007-05-10 | — | — | WO | claimed |
| EP-1478358-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | Bayer Pharmaceuticals Corporation (US) | 2004-11-24 | — | — | EP | claimed |
| US-20030207870-A1 | Aryl ureas with angiogenisis inhibiting activity | BAYER CORPORATION | 2003-11-06 | — | — | US | claimed |
| WO-2003068228-A1 | ARYL UREAS WITH ANGIOGENESIS INHIBITING ACTIVITY | BAYER PHARMACEUTICALS CORPORATION (US) | 2003-08-21 | — | — | WO | claimed |